Definity
Drugone bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Other names: Perflutren Lipid Microsphere
NCT Number: NCT00918866
The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Northwestern Memorial Hospital, Chicago, Illinois, United States
This Phase IV safety study will provide safety data on potential systemic and pulmonary hemodynamic effects caused by the administration of DEFINITY® in patients who are to undergo right heart cardiac catheterization for clinical reasons. Using a right heart catheter for direct measurements of pulmonary artery hemodynamics will allow accurate assessments of potential alterations of the pulmonary vasculature. This will be further investigated by the inclusion of two patient populations, one with a baseline pulmonary artery pressure < 35 mmHg, and one with elevated baseline pulmonary artery pressure. The addition of immune parameter measurements will assess a potential link between systemic and pulmonary alterations and potential immune reactions following DEFINITY® administration.
The inclusion of patients in this study is not based on a required echocardiogram with DEFINITY® administration because patients would be exposed to an unjustifiable risk of invasive right heart catheterization and are unlikely to consent to such a procedure. Therefore, patients undergoing heart catheterization for clinical reasons, or patients who are undergoing pulmonary artery hemodynamic assessments will be enrolled and receive DEFINITY® in this study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
Other names: Perflutren Lipid Microsphere
Time frame: 31-35 minutes minus baseline
Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose
Time frame: Out to 70 minutes
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Evaluate the Immunology Panel after the administration of DEFINITY
Time frame: Out to 70 minutes
Evaluate the Immunology Panel after the administration of DEFINITY
Lantheus Medical Imaging
Industry
A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06922916
Actinomycetales Infections, Bacterial Infections
Hangzhou, Zhejiang, China
View Trial DetailsNCT06934031
Cardiology, Cardiovascular Diseases
New Taipei City, Taiwan
View Trial DetailsNCT04863677
Cardiopulmonary Disease, Cardiovascular Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT01558076
Anemia, Anemia, Hemolytic
Chicago, Illinois, United States
View Trial Details